<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140005384A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140005384</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>14016839</doc-number><date>20130903</date></document-id></application-reference><us-application-series-code>14</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>295</main-group><subgroup>037</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>207</main-group><subgroup>34</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>295</main-group><subgroup>037</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>207</main-group><subgroup>34</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><classification-national><country>US</country><main-classification>544109</main-classification><further-classification>548537</further-classification><further-classification>544358</further-classification></classification-national><invention-title id="d0e43">Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid</invention-title><us-related-documents><division><relation><parent-doc><document-id><country>US</country><doc-number>13537432</doc-number><date>20120629</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>8552207</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>14016839</doc-number></document-id></child-doc></relation></division><division><relation><parent-doc><document-id><country>US</country><doc-number>12966488</doc-number><date>20101213</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>8236966</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>13537432</doc-number></document-id></child-doc></relation></division><division><relation><parent-doc><document-id><country>US</country><doc-number>11579656</doc-number><date>20080312</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>7875731</doc-number></document-id></parent-grant-document><parent-pct-document><document-id><country>WO</country><doc-number>PCT/IB2005/001237</doc-number><date>20050425</date></document-id></parent-pct-document></parent-doc><child-doc><document-id><country>US</country><doc-number>12966488</doc-number></document-id></child-doc></relation></division><us-provisional-application><document-id><country>US</country><doc-number>60568379</doc-number><date>20040505</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>Pfizer Inc.</orgname><address><city>New York</city><state>NY</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Campeta</last-name><first-name>Anthony Michael</first-name><address><city>Ledyard</city><state>CT</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Krzyzaniak</last-name><first-name>Joseph Francis</first-name><address><city>Pawcatuck</city><state>CT</state><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Leonard</last-name><first-name>Jason Albert</first-name><address><city>New Rochelle</city><state>NY</state><country>US</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>Pfizer Inc.</orgname><role>02</role><address><city>New York</city><state>NY</state><country>US</country></address></addressbook></assignee></assignees></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Novel salt forms of [R&#x2014;(R*,R*)]-2-(4-fluorophenyl)-&#x3b2;,&#x3b4;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.</p></abstract></us-patent-application>